Literature DB >> 27664050

Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia.

Charles Bechert1, Jee-Yeon Kim1,2, Trine Tramm3,4, Fattaneh A Tavassoli1.   

Abstract

In the USA alone, approximately 61,000 new diagnoses of ductal intraepithelial neoplasia 1c-3 (DIN) are made each year. Around 10-20 % of the patients develop a recurrence, about 50 % of which are invasive. Prior studies have shown that invasive breast carcinomas positive for p16 or p53 have a higher frequency of recurrence and a more aggressive course; however, the co-expression of these markers across the entire spectrum of DIN and its potential correlation with grade of the lesions has not been studied previously. Immunohistochemical staining for p16 and p53 was evaluated on 262 DIN lesions from 211 cases diagnosed between 1991 and 2008. The lesions ranged from DIN1b (atypical intraductal hyperplasia) to DIN3 (DCIS, grade 3) and included 45 cases with associated invasive carcinoma. Frequency of staining for both p16 and p53 increased with increasing grade of DIN. Strong co-expression was found exclusively in higher grade DIN lesions (DIN2 and DIN3) particularly those associated with periductal stromal fibrosis and lymphocytic infiltrate. Strong co-expression was seen in 8 of 12 DIN3 lesions (67 %) associated with invasive carcinoma. In conclusion, co-expression of p16 and p53 increases with advancing grade of DIN and is maximal in high grade DIN lesions associated with invasive carcinoma, indicating a more aggressive phenotype. A distinctive variant of DIN with periductal fibrosis and lymphocytic infiltrate invariably falls into the high-grade category, based on either morphology or marker expression. Co-expression of p16/p53 may be of help in distinguishing between high-grade and low-grade DIN lesions.

Entities:  

Keywords:  Ductal carcinoma in situ (DCIS); Ductal intraepithelial neoplasia (DIN); Immunohistochemistry; p16; p53

Mesh:

Substances:

Year:  2016        PMID: 27664050     DOI: 10.1007/s00428-016-2024-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  46 in total

1.  p16 expression in sentinel nodes with metastatic breast carcinoma: evaluation of its role in developing triaging strategies for axillary node dissection and a marker of poor prognosis.

Authors:  Meenakshi Singh; Mikelle B Parnes; Nicole Spoelstra; Michelle J Bleile; William A Robinson
Journal:  Hum Pathol       Date:  2004-12       Impact factor: 3.466

2.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

Review 3.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Authors:  A Sigal; V Rotter
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Authors:  Karla Kerlikowske; Annette M Molinaro; Mona L Gauthier; Hal K Berman; Fred Waldman; James Bennington; Henry Sanchez; Cynthia Jimenez; Kim Stewart; Karen Chew; Britt-Marie Ljung; Thea D Tlsty
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

Review 5.  Premalignant breast neoplasia: a paradigm of interlesional and intralesional molecular heterogeneity and its biological and clinical ramifications.

Authors:  Hal K Berman; Mona L Gauthier; Thea D Tlsty
Journal:  Cancer Prev Res (Phila)       Date:  2010-04-27

6.  INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis.

Authors:  R Hui; R D Macmillan; F S Kenny; E A Musgrove; R W Blamey; R I Nicholson; J F Robertson; R L Sutherland
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

Review 7.  The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.

Authors:  C Cadwell; G P Zambetti
Journal:  Gene       Date:  2001-10-17       Impact factor: 3.688

8.  p53 as a marker of prognosis in African-American women with breast cancer.

Authors:  Keith A Dookeran; James J Dignam; Karen Ferrer; Marin Sekosan; Worta McCaskill-Stevens; Sarah Gehlert
Journal:  Ann Surg Oncol       Date:  2010-01-05       Impact factor: 5.344

9.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

Authors:  A D Thor; I I Moore DH; S M Edgerton; E S Kawasaki; E Reihsaus; H T Lynch; J N Marcus; L Schwartz; L C Chen; B H Mayall
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506

10.  Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation.

Authors:  R Emig; A Magener; V Ehemann; A Meyer; F Stilgenbauer; M Volkmann; D Wallwiener; H P Sinn
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.